Effect and mechanism of Bufei Decoction on improving Klebsiella pneumoniae pneumonia in rats by regulating IL-17 signaling pathway.
10.19540/j.cnki.cjcmm.20250122.401
- Author:
Li-Na HUANG
1
;
Zheng-Ying QIU
2
;
Xiang-Yi PAN
2
;
Chen LIU
2
;
Si-Fan LI
2
;
Shao-Guang GE
2
;
Xiong-Wei SHI
2
;
Hao CAO
2
;
Rui-Hua XIN
2
;
Fang-di HU
1
Author Information
1. School of Pharmacy,Lanzhou University Lanzhou 730000,China.
2. Lanzhou Institute of Husbandry and Pharmaceutical Sciences,Chinese Academy of Agricultural Sciences Lanzhou 730050,China.
- Publication Type:Journal Article
- Keywords:
Bufei Decoction;
Klebsiella pneumoniae;
apoptosis;
interleukin-17(IL-17) signaling pathway;
transcriptomics
- MeSH:
Animals;
Interleukin-17/metabolism*;
Drugs, Chinese Herbal/administration & dosage*;
Rats, Sprague-Dawley;
Signal Transduction/drug effects*;
Rats;
Male;
Klebsiella pneumoniae/physiology*;
Klebsiella Infections/immunology*;
Humans;
Lung/drug effects*
- From:
China Journal of Chinese Materia Medica
2025;50(11):3097-3107
- CountryChina
- Language:Chinese
-
Abstract:
Based on the interleukin-17(IL-17) signaling pathway, this study explores the effect and mechanism of Bufei Decoction on Klebsiella pneumoniae pneumonia in rats. SD rats were randomly divided into the control group, model group, Bufei Decoction low-dose group(6.68 g·kg~(-1)·d~(-1)), Bufei Decoction high-dose group(13.36 g·kg~(-1)·d~(-1)), and dexamethasone group(1.04 mg·kg~(-1)·d~(-1)), with 10 rats in each group. A pneumonia model was established by tracheal drip injection of K. pneumoniae. After successful model establishment, the improvement in lung tissue damage was observed following drug administration. Core targets and signaling pathways were screened using transcriptomics techniques. Real-time fluorescence quantitative polymerase chain reaction was used to detect the mRNA expression of core targets interleukin-6(IL-6), interleukin-1β(IL-1β), tumor necrosis factor-α(TNF-α), and chemokine CXC ligand 6(CXCL6). Western blot was used to assess key proteins in the IL-17 signaling pathway, including interleukin-17A(IL-17A), nuclear transcription factor-κB activator 1(Act1), tumor necrosis factor receptor-associated factor 6(TRAF6), and downstream phosphorylated p38 mitogen-activated protein kinase(p-p38 MAPK), and phosphorylated nuclear factor-κB p65(p-NF-κB p65). Apoptosis of lung tissue cells was detected by terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling(TUNEL). The results showed that, compared with the control group, the model group exhibited significant pathological damage in lung tissue. The mRNA expression of IL-6, IL-1β, TNF-α, and CXCL6, as well as the protein levels of IL-17A, Act1, TRAF6, p-p38 MAPK/p38 MAPK, and p-NF-κB p65/NF-κB p65, were significantly increased, and the number of apoptotic cells was notably higher, indicating successful model establishment. Compared with the model group, both low-and high-dose groups of Bufei Decoction showed reduced pathological damage in lung tissue. The mRNA expression levels of IL-6, IL-1β, TNF-α, and CXCL6, and the protein levels of IL-17A, Act1, TRAF6, p-p38 MAPK/p38 MAPK, and p-NF-κB p65/NF-κB p65, were significantly decreased, with a significant reduction in apoptotic cells in the high-dose group. In conclusion, Bufei Decoction can effectively improve lung tissue damage and reduce inflammation in rats with K. pneumoniae. The mechanism may involve the regulation of the IL-17 signaling pathway and the reduction of apoptosis.
